Care of the menopausal patient: A nurse practitioner's view

Journal of the American Academy of Nurse Practitioners

Volumn 19, Issue 8, 2007, Pages 427-437

  Dehn, Barbara ^a  

^a Women Physicians OB/GYN Medical Group   (United States)

Author keywords

Estrogen; Hormone therapy; Menopausal symptoms; Menopause

Indexed keywords

ANAMNESIS; ARTICLE; COUNSELING; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; LIFESTYLE; MENOPAUSE; METHODOLOGY; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; PATIENT CARE PLANNING; PATIENT EDUCATION; PATIENT SELECTION; PHYSIOLOGY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SAFETY; WOMEN'S HEALTH;

ATTITUDE OF HEALTH PERSONNEL; COUNSELING; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIFE STYLE; MEDICAL HISTORY TAKING; MENOPAUSE; NURSE PRACTITIONERS; NURSE'S ROLE; NURSING ASSESSMENT; PATIENT CARE PLANNING; PATIENT EDUCATION; PATIENT SELECTION; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SAFETY; WOMEN'S HEALTH;

EID: 34547510917     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2007.00246.x     Document Type: Article

References (83)

1. Aldrighi, J. M., Quail, D. C., Levy-Frebault, J., Aguas, F., Kosian, K., Garrido, L., et al 2004). Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. American Journal of Obstetrics and Gynecology, 191, 1979 1988.
2. American College of Obstetricians and Gynecologists 2003). Questions and answers on hormone therapy [News release]. Retrieved May 15, 2006, from http://www.acog.org/from_home/publications/press_releases/nr08-30-02.cfm
3. American College of Obstetricians and Gynecologists Women's Health Care Physicians 2004a). Breast cancer. Obstetrics and Gynecology, 104 (Suppl. 4 11S 16S.
4. American College of Obstetricians and Gynecologists Women's Health Care Physicians 2004b). Coronary heart disease. Obstetrics and Gynecology, 104 (Suppl. 4 41S 48S.
5. American College of Obstetricians and Gynecologists Women's Health Care Physicians 2004c). Executive summary. Hormone therapy. Obstetrics and Gynecology, 104 (Suppl. 4 1S 4S.
6. American College of Obstetricians and Gynecologists Women's Health Care Physicians 2004d). Genitourinary tract changes. Obstetrics and Gynecology, 104 (Suppl. 4 56S 61S.
7. American College of Obstetricians and Gynecologists Women's Health Care Physicians 2004e). Osteoporosis. Obstetrics and Gynecology, 104 (Suppl. 4 66S 76S.
8. American College of Obstetricians and Gynecologists Women's Health Care Physicians 2004f). Vasomotor symptoms. Obstetrics and Gynecology, 104 (Suppl. 4 106S 117S.
9. Archer, D. F 2005). Lower doses of oral estrogen and progestogens as treatment for postmenopausal women. Seminars in Reproductive Medicine, 23 (2 188 195.
10. Archer, D. F., Dorin, M., Lewis, V., Schneider, D. L. Pickar, J. H 2001). Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertility and Sterility, 75, 1080 1087.
11. Baird, D. D., Umbach, D. M., Lansdell, L., Hughes, C. L., Setchell, K. D., Weinberg, C. R., et al 1995). Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. Journal of Clinical Endocrinology Metabolism, 80 (5 1685 1690.
12. Boothby, L. A., Doering, P. L. Kipersztok, S 2004). Bioidentical hormone therapy: A review. Menopause, 11 (3 356 367.
13. Bygdeman, M. Swahn, M. L 1996). Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas, 23 (3 259 263.
14. Cardozo, L., Bachmann, G., McClish, D., Fonda, D. Birgerson, L 1998). Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee. Obstetrics and Gynecology, 92 (4, Pt. 2 722 727.
15. Cardozo, L., Lose, G., McClish, D., Versi, E. de Koning Gans, H 2001). A systematic review of estrogens for recurrent urinary tract infections: Third report of the hormones and urogenital therapy (HUT) committee. International Urogynecology Journal and Pelvic Floor Dysfunction, 12 (1 15 20.
16. Cauley, J. A., Robbins, J., Chen, Z., Cummings, S. R., Jackson, R. D., LaCroix, A. Z., et al Women's Health Initiative Investigators 2003). Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA, 290 (13 1729 1738.
17. Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., et al Women's Health Initiative Investigators 2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA, 289 (24 3243 3253.
18. Chlebowski, R. T., Wactawski-Wende, J., Ritenbaugh, C., Hubbell, F. A., Ascensao, J., Rodabough, R. J., et al Women's Health Initiative Investigators 2004). Estrogen plus progestin and colorectal cancer in postmenopausal women. New England Journal of Medicine, 350 (10 991 1004.
19. Cobin, R 1999). American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocrine Practice, 5, 354 366.
20. Cummings, S. R., Black, D. M., Thompson, D. E., Applegate, W. B., Barrett-Connor, E., Musliner, T. A., et al 1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA, 280 (24 2077 2082.
21. Curb, J. D., Prentice, R. L., Bray, P. F., Langer, R. D., Van Horn, L., Barnabei, V. M., et al 2006). Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine, 166 (7 772 780.
22. Cushman, M., Kuller, L. H., Prentice, R., Rodabough, R. J., Psaty, B. M., Stafford, R. S., et al Women's Health Initiative Investigators 2004). Estrogen plus progestin and risk of venous thrombosis. JAMA, 292 (13 1573 1580.
23. Delmas, P. D., Ensrud, K. E., Adachi, J. D., Harper, K. D., Sarkar, S., Gennari, C., et al Multiple Outcomes of Raloxifene Evaluation Investigators 2002). Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. Journal of Clinical Endocrinology Metabolism, 87 (8 3609 3617.
24. Dodin, S., Lemay, A., Jacques, H., Legare, F., Forest, J. C. Masse, B 2005). The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: A randomized, double-blind, wheat germ placebo-controlled clinical trial. Journal of Clinical Endocrinology Metabolism, 90, 1390 1397.
25. Ettinger, B., Ensrud, K. E., Wallace, R., Johnson, K. C., Cummings, S. R., Yankov, V., et al 2004). Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial. Obstetrics and Gynecology, 104 (3 443 451.
26. Fugate, S. E. Church, C. O 2004). Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Annals of Pharmacotherapy, 38 (9 1482 1499.
27. Genant, H. K., Lucas, J., Weiss, S., Akin, M., Emkey, R., McNaney-Flint, H., et al 1997). Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Archives of Internal Medicine, 157, 2609 2615.
28. Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D., Ettinger, B., et al 1992). Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine, 117, 1016 1037.
29. Greenspan, S. L., Emkey, R. D., Bone, H. G., Weiss, S. R., Bell, N. H., Downs, R. W., et al 2002). Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine, 137 (11 875 883.
30. Grodstein, F., Newcomb, P. A. Stampfer, M. J 1999). Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. American Journal of Medicine, 106 (5 574 582.
31. Grodstein, F., Stampfer, M. J., Manson, J. E., Colditz, G. A., Willett, W. C., Rosner, B., et al 1996). Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New England Journal of Medicine, 335, 453 461.
32. Hendrix, S. L., Wassertheil-Smoller, S., Johnson, K. C., Howard, B. V., Kooperberg, C., Rossouw, J. E., et al 2006). Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation, 113 (20 2425 2434.
33. Henriksson, L., Stjernquist, M., Boquist, L., Cedergren, I. Selinus, I 1996). A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. American Journal of Obstetrics and Gynecology, 174 (1, Pt. 1 85 92.
34. Hersh, A. L., Stefanick, M. L. Stafford, R. S 2004). National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA, 291 (1 47 53.
35. Hogervorst, E., Williams, J., Budge, M., Riedel, W. Jolles, J 2000). The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: A meta-analysis. Neuroscience, 101 (3 485 512.
36. Hsia, J., Langer, R. D., Manson, J. E., Kuller, L., Johnson, K. C., Hendrix, S. L., et al Women's Health Initiative Investigators 2006). Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Archives of Internal Medicine, 166, 357 365.
37. Hu, F. B., Grodstein, F., Hennekens, C. H., Colditz, G. A., Johnson, M., Manson, J. E., et al 1999). Age at natural menopause and risk of cardiovascular disease. Archives of Internal Medicine, 159 (10 1061 1066.
38. Johnson, S. R., Ettinger, B., Macer, J. L., Ensrud, K. E., Quan, J. Grady, D 2005). Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstetrics and Gynecology, 105 (4 779 787.
39. Kaunitz, A. M 2001). Oral contraceptive use in perimenopause. American Journal of Obstetrics and Gynecology, 185 (Suppl. 2 S32 S37.
40. Krebs, E. E., Ensrud, K. E., MacDonald, R. Wilt, T. J 2004). Phytoestrogens for treatment of menopausal symptoms: A systematic review. Obstetrics and Gynecology, 104, 824 836.
41. Kreijkamp-Kaspers, S., Kok, L., Grobbee, D. E., de Haan, E. H., Aleman, A., Lampe, J. W., et al 2004). Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: A randomized controlled trial. JAMA, 292, 65 74.
42. Lindsay, R., Gallagher, J. C., Kleerekoper, M. Pickar, J. H 2002). Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA, 287, 2668 2676.
43. Lobo, R. A 2004a). The rationale for low-dose hormonal therapy. Endocrine, 24 (3 217 221.
44. Lobo, R. A 2004b). Views on recent trials and the future of hormonal therapy. Clinical Obstetrics and Gynecology, 47 (2 424 427.
45. Loh, F. H., Chen, L. H., Yu, S. L. Jorgensen, L. N 2002). The efficacy of two dosages of a continuous combined hormone replacement regimen. Maturitas, 41 (2 123 131.
46. Lookinland, S. Beckstrand, R. L 2003). HRT: Decide based on the evidence. Nurse Practitioner, 28 (9 46 54.
47. Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., et al 2000). Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet, 356, 2059 2063.
48. Lucas, E. A., Wild, R. D., Hammond, L. J., Khalil, D. A., Juma, S., Daggy, B. P., et al 2002). Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 87, 1527 1532.
49. MacLennan, A. H., Broadbent, J. L., Lester, S. Moore, V 2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Systematic Reviews, (4 CD002978. doi: 10.1002/14651858.CD002978.pub2
50. Mahady, G. B., Parrot, J., Lee, C., Yun, G. S. Dan, A 2003). Botanical dietary supplement use in peri- and postmenopausal women. Menopause, 10, 65 72.
51. Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., et al Women's Health Initiative Investigators 2003). Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine, 349 (6 523 534.
52. Mizunuma, H., Okano, H., Soda, M., Kagami, I., Miyamoto, S., Tokizawa, T., et al 1997). Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study. Maturitas, 27, 69 76.
53. Naftolin, F., Taylor, H. S., Karas, R., Brinton, E., Newman, I., Clarkson, T. B., et al Women's Health Initiative 2004). The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertility and Sterility, 81 (6 1498 1501.
54. Nanda, K., Bastian, L. A., Hasselblad, V. Simel, D. L 1999). Hormone replacement therapy and the risk of colorectal cancer: A meta-analysis. Obstetrics and Gynecology, 93 (5, Pt. 2 880 888.
55. National Osteoporosis Foundation 2007). Physician's guide to prevention and treatment of osteoporosis. Washington, DC : Author.
56. Nikander, E., Rutanen, E. M., Nieminen, P., Wahlstrom, T., Ylikorkala, O. Tiitinen, A 2005). Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women. Fertility and Sterility, 83, 137 142.
57. Nilsson, K. Heimer, G 1995). Low-dose 17 beta-oestradiol during maintenance therapy - A pharmacokinetic and pharmacodynamic study. Maturitas, 21 (1 33 38.
58. North American Menopause Society 2004a). Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause, 11 (1 11 33.
59. North American Menopause Society 2004b). Treatment of menopause-associated vasomotor symptoms: Position statement of The North American Menopause Society. Menopause, 11 (1 11 33.
60. Notelovitz, M. Mattox, J. H 2000). Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause, 7 (5 310 317.
61. Ockene, J. K., Barad, D. H., Cochrane, B. B., Larson, J. C., Gass, M., Wassertheil-Smoller, S., et al 2005). Symptom experience after discontinuing use of estrogen plus progestin. JAMA, 294 (2 183 193.
62. Phillips, L. S. Langer, R. D 2005). Postmenopausal hormone therapy: Critical reappraisal and a unified hypothesis. Fertility and Sterility, 83 (3 558 566.
63. Pickar, J. H., Yeh, I.-T., Wheeler, J. E., Cunnane, M. F. Speroff, L 2001). Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility, 76, 25 31.
64. Pickar, J. H., Yeh, I.-T., Wheeler, J. E., Cunnane, M. F. Speroff, L 2003). Effects of 2 years of treatment with lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial safety. Fertility and Sterility, 80, 1234 1240.
65. Potter, S. M., Baum, J. A., Teng, H., Stillman, R. J., Shay, N. F. Erdman, J. W., Jr. 1998). Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. American Journal of Clinical Nutrition, 68, 1375S 1379S.
66. Schapira, M. M., Gilligan, M. A., McAuliffe, T. L. Nattinger, A. B 2004). Menopausal hormone therapy decisions: Insights from a multi-attribute model. Patient Education and Counseling, 52 (1 89 95.
67. Shumaker, S. A., Legault, C., Kuller, L., Thal, L., Lane, D. S., Fillit, H., et al Women's Health Initiative Memory Study. (2004). Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA, 291 (24 2947 2958.
68. Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., et al WHIMS Investigators 2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA, 289 (20 2651 2662.
69. Smith, P. E 2005). Menopause assessment, treatment, and patient education. Nurse Practitioner, 30 (2 32 43.
70. Speroff, L 2004). Postmenopausal hormone therapy and the risk of breast cancer. A clinician's view. Maturitas, 49 (1 51 57.
71. Stearns, V., Beebe, K. L., Iyengar, M. Dube, E 2003). Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. JAMA, 289, 2827 2834.
72. Steefel, L 2004). Hormone therapy for menopausal symptoms - Update for the clinical nurse specialist. Clinical Nurse Specialist, 18 (1 14 15.
73. Stefanick, M. L., Anderson, G. L., Margolis, K. L., Hendrix, S. L., Rodabough, R. J., Paskett, E. D., et al 2006). Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA, 295 (14 1647 1657.
74. Tice, J. A., Ettinger, B., Ensrud, K., Wallace, R., Blackwell, T. Cummings, S. R 2003). Phytoestrogen supplements for the treatment of hot flashes: The Isoflavone Clover Extract (ICE) Study: A randomized controlled trial. JAMA, 290, 207 214.
75. Uesugi, T., Fukui, Y. Yamori, Y 2002). Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: A four-week study. Journal of the American College of Nutrition, 21, 97 102.
76. Utian, W. H 2005). Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review. Health and Quality of Life Outcomes, 3 (1 47.
77. Utian, W. H., Burry, K. A., Archer, D. F., Gallagher, J. C., Boyett, R. L., Guy, M. P., et al 1999). Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. American Journal of Obstetrics and Gynecology, 181, 71 79.
78. Utian, W. H., Shoupe, D., Bachmann, G., Pinkerton, J. V. Pickar, J. H 2001). Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility, 75, 1065 1079.
79. Walter, F. M., Emery, J. D., Rogers, M. Britten, N 2004). Women's views of optimal risk communication and decision making in general practice consultations about the menopause and hormone replacement therapy. Patient Education and Counseling, 53 (2 121 128.
80. Wassertheil-Smoller, S., Hendrix, S. L., Limacher, M., Heiss, G., Kooperberg, C., Baird, A., et al. Women's Health Initiative Investigators 2003). Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA, 289 (20 2673 2684.
81. Women's Health Initiative Steering Committee 2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA, 291 (14 1701 1712.
82. Wysocki, S., Alexander, I., Schnare, S. M., Moore, A. Freeman, S 2003). Individualized care for menopausal women: Counseling women about hormonal therapy. Women's Health Care: A Practical Journal for Nurse Practitioners, 2 (2 8 16.
83. Yaffe K., Sawaya G., Lieberburg I., Grady D. (1998). Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 279, 9. 688-695.